$12.04
FibroGen
Performance
Dividends
-6.3%
1W
1M
YTD
1Y
3Y
About
Pursuing groundbreaking science to create new standards of patient care in anemia and an array of serious fibrotic conditions.
Twitter
Web
Share
18/36
Growth Score
7/36
Dividend Score
Valuation
PE Ratio
-3.94
PS Ratio
4.86
3
RSI
44.33
0
PEG Ratio
4.53
0
PRG Ratio
-0.07
PDG Ratio
0
Growth
0-31%233%0-35%355%
-146%-53%-1%41%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
60.03%
3
Gross Margin
94.53%
2
Current Ratio
2.1
Return on Assets
-37.48%
Return on Equity
-99.45%
Return on inv. Capital
-52.62%
Institutional Holder
71.036.426069.333.317
1362169
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2021 235.31M
34%31%0%-30%69%20%-31%33%
2014
2015
2016
2017
2018
2019
2020
2021
7
Net Income 2021 -290.02M
-298%-44%28%-104%31%10%-145%-53%
2014
2015
2016
2017
2018
2019
2020
2021
7
Gross Profit 2021 222.44M
-100%-34%32%
2014
2015
2016
2017
2018
2019
2020
2021
7
What will move the market
These are the numbers that will move the market, and the guidance that will move it as well.
-$0.81
99.96% YoY
EPS
31.12M
25.50% YoY
Revenue
Current Quarter Analyst Estimates
-$0.8
100.45% YoY
EPS
34.83M
49.60% YoY
Revenue
Next Quarter Analyst Estimates
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
14.11.2014
MaketCap
1.14B
Country
US
CEO
Mr. Enrique Conterno
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Updated 15.03.2022